Le Lézard
Classified in: Health
Subject: PLW

eprestm Awarded Patent for Next-Generation Bond Repair Technology

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- eprestm: the next generation in high-performance haircare is proud to announce that the Patent and Trademark Office (USPTO) has awarded Dr. Eric Pressly US Patent No. 11,491,092 for the brand's molecular technology that repairs disulfide bonds.

The patented research was done by Dr. Eric Pressly, PhD who holds more than 100 patents in bond-repair technology and considers eprestm to be his best invention yet. The patent is a transformative piece of intellectual property that the brand is using to revolutionize the haircare industry with their proprietary technology that continues to transform the hair long after it dries.

In salon, the Professional Bond Repair works as a single-step solution to actively re-bond hair structure without lowering the pH balance of the chemical service, which prevents increased processing times, reduced lift, and inhibited color deposit. For consumers at home, the Bond Repair Treatment Kit comes with an eprestm spray bottle and two water-free concentrate vials. Its formula actively re-bonds hair's structure adding lasting softness, strength, and manageability; its unique liquid-molecule technology continues to diffuse repair throughout each strand for hours after application. After initial purchase, consumers can shop the water-free concentrate vials separately.  

This is first patent awarded to eprestm and the brand will continue to leverage its use of next-generation bond repair technology to develop and validate new innovations in the future. "Being awarded this patent confirms the credible science behind the formulation and the efficacious results," said Eric Pressly, Founder of eprestm. "My motivation for developing this patented technology was to implement unique advancements into the bond-building space that the world has never seen before. For the past few years, I worked extensively to establish a technology that would allow liquid molecules to continue to move and explore the hair, looking for areas of damage in just one simple step."

For more information, please visit epres.com.

About eprestm:

Founder, Eric Pressly, first discovered his talent for innovation while pursuing his Ph.D. in materials science, working on everything from developing life-saving pharmaceuticals to inventing the bond-building category in haircare. Now he has created eprestm the next generation in high-performance haircare. The product range features two first-of-its kind, acid free, bond-building treatments available in the professional and consumer space. Each of the products are equipped with unprecedented Biodiffusiontm technology, which continues to move and repair even after the hair is dry.

SOURCE eprestm

These press releases may also interest you

at 18:00
Aurora Cannabis Inc. ("Aurora" or the "Company") , the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023,...

at 17:30
Cybeats Technologies Corp. ("Cybeats'' or the "Company") is pleased to announce the commencement of a trial evaluation with one of the top-3 largest software companies by total revenue, for Cybeats SBOM Studio.1...

at 17:30
Western University of Health Sciences' College of Osteopathic Medicine of the Pacific (COMP) and COMP-Northwest celebrated 100% residency placement on Match Day, compared to the averages across all other medical schools with match rates of 91.6% for...

at 17:00
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today announced that the Toronto Stock Exchange has approved its notice of intention to make a normal course issuer bid for a portion of its subordinate voting shares ("Shares") as appropriate...

at 17:00
Pieris Pharmaceuticals, Inc. ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host...

at 16:35
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate...

News published on 3 january 2023 at 09:00 and distributed by: